Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MLHW Announces Extension of Reexamination Period for Lonasen
November 29, 2011
- JAN Determined for 8 Drug Candidate Compounds
November 29, 2011
- Record 101 Generics from 30 Companies Listed for Aricept
November 29, 2011
- MHLW Says Sept Drug Price Settlement Rate Dips to 78.1%, Falling Below 2009 Level
November 28, 2011
- MHLW Issues Notification on Modifications of Approval for Iressa
November 28, 2011
- CSIMC to Discuss Additional Price Cuts for Long-Listed Drugs
November 28, 2011
- DPJ's Subcommittee for PAL Amendment Begins Deliberations Nov. 28, to Compile Opinion by End-Jan
November 25, 2011
- Obligatory Use of Generics for Welfare Recipients to Be Discussed: Policy Screening
November 25, 2011
- HPB, HSB Issue Notification to Ensure Stable Supplies of Flu Drugs This Season
November 25, 2011
- Experts Call For Establishment of Independent Vaccine Policy Organization
November 25, 2011
- Otsuka to Challenge Grand Champion Santen in Market for Dry Eye Treatments
November 25, 2011
- Policy Screening Committee Proposes Major Cutbacks in Long-Listed Drug Prices, Additional Decreases Possible
November 24, 2011
- Patients’ Copayments for OTC-like Drugs to Be Increased on a Trial Basis: Policy Screening
November 24, 2011
- Council Approves New 10-Year Strategy for Hepatitis Research
November 24, 2011
- MHLW Council Approves Subsidizing Telaprevir Combination Therapy
November 24, 2011
- DPJ WT to Propose New Measures to Promote Generics
November 24, 2011
- Committee on OTC Drugs Recommends SSP’s Vaginal Candidiasis Treatment for Approval
November 24, 2011
- Korosho Issues Notification to Ensure Stable Supplies of Flu Drugs This Season
November 24, 2011
- Korosho’s Council Approves Subsidizing 3-Drug Combination Therapy Including Teraprevir
November 22, 2011
- MHLW Study Group Postpones Decision on Relief System for Victims of Health Damages Due to Anticancer Drugs
November 21, 2011
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…